Not Specified

• A weight management program for the severely mentally Ills
• Altered resting state functional connectivity of anterior cingulate cortex in obsessive-compulsive disorder
• Antipsychotic drug treatments: Evoling treatment statergies
• Antipsychotic drug treatments: The use of polypharmacy to get improved outcomes
• BDNF pharmacogenetics of methamphetamine abuse
• Bipolar depression: diagnostic and management issues
• Bipolar disorder and its mangement: overview
• Bipolar Disorder: Journey from Pole to Pole Atypical Antipsychotic in the Management of Mood Disorder
• Boundaries of bipolar disorders and adequacy of treatment
• Building blocks of new psychiatric services: post Mental Health Act 2001
• Candidate genes for response to risperidone: from mouse to man
• Cognitive function in euthymic state of bipolar disorders: association of brain serotonin transporter and brain derived neurotrophic factor
• Deinstitutionalization in Malaysia: a Myth or Reality?
• Do women benefit more from antipsychotics than men?
• Evidence for genetic variants in the melanocortin system predicting antipsychotic induced weight gain
• Glutamatergic pharmacogenetics of methamphetamine abuse and psychosis
• Harm reduction in custodial settings in Malaysia
• Harm reduction: An update and pharmacological aspects
• History of drug use and epidemiological aspects of drug use in Malaysia
• HIV and mental health
• Home care in Malaysia: does it improve patients' care
• Hormone modulation: A novel approach to managing mental illness in women?
• Influence and interaction of genetic polymorphisms in the monoaminergic system and life stress on antidepressant drug response
• Modelling cognitive deficit symptoms in schizophrenia: Emerging Targets
• Near-infrared spectroscopy as a possible biomarker for predicting effect of methylphenidate in children with ADHD
• Neurochemical changes in the CNS of people with bipolar disorders
• Neuronal mechanisms of methamphetamine-seeking behaviour
• Neuropeptide S system in arousal, anxiety and panic disorder
• Novel biomarkers for schizophrenia in Malaysian population
• Optimizing treatment outcomes in patients with schizophrenia
• Perhipheral biomarkers for psychosis
• Pharmacogenetics of symptom response to antipsychotic treatment
• Progress in neuroimaging studies of high-risk subjects for psychosis and its relation to clinical psychopathology
• Separating schizophernia - what do microarrays of the CNS tell us?
• Social stress and defeat, from circuits to methylation - exploring stress-induced alterations in neurobiology that drive changes in behavioural state and cognitive function in the adult rat
• Special issues for women with bipolar affective disorder
• Spiritual enhancement drug addiction rehabilitation (SEDAR) An innovative platform for up scaling harm reduction in Malaysia
• Structural renal changes under long-term treatment with lithium - a 3T MR study
• Targeting the cholinergic system to treat schizophrenia: An old concept with promising new directions
• The effects of methamphetamine on glutamatergic systems
• The effects of pharmacotherapy on brain in patients with OCD
• The metabolic effects of ziprasidone versus Olanzapine in first-episode schizophrenia: a 6-week, multicenter, randomized, flexible-dose study
• The national register of antipsychotic medication in pregnancy (NRAMP), The first 100 women.
• The neuropsychopharmacology of antidepressants and potential new mechanisms of action
• The place of antidepressants in the complex treatment of depressive patients
• The role of cognitive remediation therapy (CRT) in psychosocial rehabilitation
• The role of inflammatory-related pathways in the pathophysiology of major depressive disorders and bipolar disorders
• The search for biomarkers in psychiatric disorders: Studies of the human CNS proteome
• Treating depression - Current best practice

49 abstracts